Monograph Details
|
|
Neoplasms
> Antimicrotubule agents
|
|
VINCASAR PFS |
| Manufacturer |
|
Teva Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antimicrotubule agent. |
| Generic Name |
|
Vincristine sulfate 1mg/mL; soln for IV inj; contains mannitol; preservative-free. |
| Indications |
|
Acute leukemia. In combination with other chemotherapeutic agents for Hodgkin's disease, non-Hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, diffuse types), rhabdomyosarcoma, neuroblastoma, Wilms' tumor. |
| Children |
|
≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly. |
| Adults |
|
Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%. |
| Contraindications |
|
Demyelinating form of Charcot-Marie-Tooth syndrome. |
| Precautions |
|
For IV use only; fatal if given intrathecally. Hepatic dysfunction. Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended. |
| Interactions |
|
Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy. |
| Adverse Reactions |
|
GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy. |
| How Supplied |
|
Single-use vials (1mL, 2mL)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
